PPT-Diabetic Retinopathy Market: Global Market Insights, Inc

1
Diabetic Retinopathy Market 2016 2023
2
Global Market Scenario of Diabetic Retinopathy

• Diabetic Retinopathy Market size was USD 6.5
  billion in 2015, with the global industry
  anticipating 6.9 CAGR growth from 2016 to 2023.
• Increasing global geriatric population
  prevalence, rising diabetes occurrence, rapid
  increase in incidence of blindness associated
  with diabetes, and strong awareness for early
  detection of diabetic retinopathy will be pivotal
  factors for driving global diabetic retinopathy
  market demand.
• Geriatric population growth will significantly
  impact the diabetic retinopathy market, since
  aging is considered to be greatest risk factor
  for chronic conditions.
• Diabetes is considered to be leading a cause for
  blindness among people. As per the estimates by
  DARS (Department of Assistive and Rehabilitative
  Services, Texas), in the year 2013, more than 77
  cases of diabetic retinopathy were reported. 
• https//www.gminsights.com/industry-analysis/diabe
  tic-retinopathy-market

3
Continue.....

• The diabetic retinopathy market is showcasing
  various technological advancements led by the
  introduction of better performing lenses and
  instruments.
• Technological innovations in retinal screening
  techniques and instruments such as use of slit
  lamps, and introduction of innovative products
  such as Optina, and Gly-230 will drive diabetic
  retinopathy market.
• Rising prevalence of diabetes should further
  enhance the market growth. Diabetes is expected
  to affect over an estimated 4.5 of global
  population. The global burden of diabetes was
  over 366 million in 2011, which is expected to
  reach over 552 million by the end of 2030.
• Get detail report _at_
• https//www.gminsights.com/industry-analysis/diabe
  tic-retinopathy-market

4
U.S. Diabetic Retinopathy Market size, by
management, 2012 - 2023 (USD Million)

https//www.gminsights.com/industry-analysis/diabe
tic-retinopathy-market
5
360 Analysis

• Application Analysis
• Growing prevalence of diabetes and rising number
  of geriatric population expected to acquire
  retinopathy proliferative stage should boost the
  demand for the same. In terms, of diabetic
  retinopathy management, anti-VEGF occupies a
  significant chunk, followed by intra-ocular
  steroid injections, vitrectomy, and laser surgery
  respectively in 2015, owing to popular usage of
  these drugs in treatment of early diagnosis and
  mild to moderate cases of non-proliferative
  treatment.  
• Regional Analysis
• North America was the largest regional avenue
  driven by U.S., with revenue target of more than
  USD 4 billion by 2023.
• U.S. diabetic retinopathy prevalence rate was
  estimated to be 5.4 nationally as stated by
  Prevent Blindness America in 2012, with New
  Mexico, California, Texas, New York, Arizona and
  Florida having the highest density of all.
•  
• Competitive Market Share
• Global diabetic retinopathy market was dominated
  by Regeneron Pharmaceuticals, Inc. and Bayer
  Pharmaceuticals collectively grabbing more than
  40 share in the overall market in 2015 majorly
  owing to high market penetration rates of Eylea
  in regions outside the U.S. Other active
  participants include Novartis, Actavis, BCN
  Peptides, Kowa Group, Ampio Pharmaceuticals, and
  ThromboGenics, among others.

6

Latest Research Report On Diabetic Retinopathy
Market _at_ https//www.gminsights.com/industry-analy
sis/diabetic-retinopathy-market Download
Latest Report PDF _at_ https//www.gminsights.com/req
uest-sample/detail/486
7
Stay In Touch You can visit us at
www.gminsights.com